



# 2007 Pediatric Academic Societies' Annual Meeting

May 5–May 8 ~ Toronto, Canada

**Daily Schedule:  
Friday, May 4**

**Legend: TCC=Toronto Convention Center**

**FRY=Fairmont Royal York**

(as of March 14, 2007)

7:30am–9:00am

## **4100A Pediatric Palliative Care: The Team Approach to a Child's and Family's End of Life Needs**

ASPHO Workshop ~ FRY, Confederation 5-6

### Objectives:

- Address symptom and pain management problems for pediatric patients at the end of life
- Develop strategies to improve communication with pediatric patients at the end of life and their families
- Discuss ethical issues surrounding end of life care for pediatric patients

Chairs: Linda Granowetter, Columbia University College of Physicians and Surgeons, and the Morgan Stanley Children's Hospital of New York Presbyterian, New York, NY; and John Saroyan, Columbia University College of Physicians and Surgeons, and the Morgan Stanley Children's Hospital of New York Presbyterian, New York, NY

Care of children and their families at the end of life is a significant challenge for all of us who work in oncology, bone marrow transplant and hematology. Using a case-based approach we will explore the many issues that arise in regard to pain management, psychological and spiritual care, communication, and ethical issues. The goal of this workshop is to improve the participant's ability to care for patients at the end of life, and to better care for their families.

7:30am–9:00am

## **4105A Practice Management: Planning for the Future**

ASPHO Workshop ~ FRY, Territories

### Objectives:

- Discuss how evolving trends in clinical practice, research opportunities and patient populations will impact the workload and job responsibilities for pediatric hematologists/oncologists over the next 5-10 years
- Assess the factors that contribute to the workload for physicians in this field and develop a method to determine manpower requirements for a given practice
- Evaluate if current training of pediatric hematology/oncology fellows provides them with the requisite skills to meet their anticipated job requirements and career aspirations
- Identify key factors for both practitioners and practices as physicians elect to transition out of clinical practice

Chair: Eric J. Werner, Children's Hospital of The King's Daughters and Eastern Virginia Medical School, Norfolk, VA

The median age of pediatric hematologists/oncologists is currently about 52 years. This workshop will discuss how practices and practitioners of our specialty must plan for the anticipated changes in physician availability in the future. Considering evolving trends and advances in clinical care, the speakers will give an assessment of what the pediatric hematology/oncology practice of the future will look like and how to estimate expected workforce needs, particularly for physicians, in the future. The issue as to whether current training of fellows is congruent to the anticipated roles and responsibilities of these specialists will be addressed. Finally, issues relating to current practitioners transitioning out of active clinical practice will be discussed.

7:30am–9:00am

## **4110A Young Investigators**

ASPHO Workshop ~ FRY, Tudor 7-8

### Objectives:

- Discuss how to identify a mentor, and how to become a mentor to others
- Describe the promotion process in an academic institution
- Identify grant agencies and funding opportunities for senior fellows and junior faculty

Chair: Kathleen M. Sakamoto, Mattel Children's Hospital, David Geffen School of Medicine at UCLA, Los Angeles, CA

This workshop will provide an opportunity for fellows and junior faculty to learn about mentorship (being a mentor and being mentored); promotion process in academic careers; and research grants. The following topics will be covered: mentorship, giving and receiving--the key to life-long professional development; understanding the promotion process and climbing the academic ladder; and funding opportunities for senior fellows and junior faculty. Presentations will be followed by question and answer sessions and opportunity for discussion.

9:15am–11:15am

### **4200A Relapsed ALL**

ASPHO Symposium ~ FRY, Ballroom

Objectives:

- Describe the biological features of relapsed ALL, and compare and contrast with newly diagnosed ALL
- Discuss the appropriate use of transplant for children with relapsed ALL
- Describe new agents with activity in ALL

Chair: Stella Davies, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

This 2 hour session will address the difficult clinical problem of relapsed ALL. We will review the biology of relapsed ALL, and compare and contrast the characteristics of leukemic blasts at relapse with newly diagnosed disease. There will follow a presentation regarding the role of allogeneic transplant in the treatment of relapsed ALL, discussing timing, conditioning therapy and donor source. The last presentation will describe non-transplant approaches to relapsed ALL, with particular focus on new agents that may have activity in relapsed ALL.

#### **9:15 Biology of Relapsed ALL**

William L. Carroll, NYU Children's Health, New York, NY

#### **9:55 The Role of Allogeneic Transplant in the Treatment of Relapsed ALL**

Mary Eapen, Medical College of Wisconsin, Milwaukee, WI

#### **10:35 Non-transplant Approaches to Relapsed ALL**

Lia Gore, The University of Colorado Cancer Center and the Children's Hospital, Denver, CO

11:30am–1:00pm

### **Preserving Joint Function in Individuals with Severe Hemophilia and von Willebrand Disease: The Importance of Early Intervention**

ASPHO Corporate Forum Satellite Luncheon Symposia

FRY, Ontario

1:15pm–3:15pm

### **4400A Hemoglobinopathies—To BMT or Not to BMT?**

ASPHO Symposium ~ FRY, Territories

Objectives:

- Identify when BMT is indicated for a child with hemoglobinopathy
- Identify when BMT is not indicated for a child with hemoglobinopathy

Chair: Jakub Tolar, University of Minnesota, Minneapolis, MN

A large number of children suffer from hemoglobinopathies which can be treated by conventional means or by BMT. As multiple scenarios exist – taking into account the severity of the disease itself, age of the child, availability of conditioning regimens of different intensity, possibility of related or unrelated donors and bone marrow and cord blood grafts – this symposium will address these issues and provide a realistic overview of indications and outcomes of BMT.

BMT and non BMT approaches have been utilized to treat children with hemoglobinopathies. The need for BMT must be evaluated with caution, however, as this approach carries some nontrivial dangers for the patients, such as regimen related toxicities, graft-versus-host disease, endocrinopathies, sterility and second malignancies. On the other hand BMT may offer a permanent cure and delay in treatment may result in high morbidity and mortality from the hemoglobinopathy itself. The program will begin with presentations of the most recent data outcomes of either therapeutic approach by pediatric and adult hematologists. The program will follow with a perspective of a bone marrow transplant. The symposium will conclude with a debate and panel discussion with the audience and a perspective of a patient advocate. While both conventional therapies and BMT have yielded some notable successes and hold considerable promise, one should walk away from the session with a realistic overview of the possibilities and limitations of BMT for childhood hemoglobinopathies.

#### **1:15 Introduction**

Jakub Tolar, University of Minnesota, Minneapolis, MN

#### **1:20 View of a Pediatric Hematologist**

Kwaku Ohene-Frempong, Children's Hospital of Philadelphia, Philadelphia, PA

#### **1:40 View of an Adult Hematologist**

H. Franklin Bunn, Brigham and Women's Hospital, Boston, MA

#### **2:00 View of a Transplanter**

Lakshmanan Krishnamurti, Children's Hospital of Pittsburgh, Pittsburgh, PA

#### **2:20 Sickle Cell Disease: A Parent Perspective**

Andrea Williams, Children's Sickle Cell Foundation, Inc., Pittsburgh, PA

#### **2:40 Panel Discussion**

1:15pm–3:15pm

## **4405A Osteosarcoma: What's New and What's Needed**

ASPHO Symposium ~ FRY, Ballroom

### Objectives:

- Describe novel agents and the rationale for their use in treating OS patients
- Discuss challenges and improvements to endoprosthetic development
- Discuss the use of international studies to advance survival in OS patients

Chair: Jeffrey A. Toretsky, Lombardi Comprehensive Cancer Center and Pediatrics, Washington, DC

Osteosarcoma developments in both orthopedic and medicinal approaches are evolving. This session will update participants with state-of-the-art knowledge in limb reconstructive surgery. Current novel approaches to Osteosarcoma include the use of biologic response modifiers and direct pulmonary therapy. This session will discuss these novel approaches and how they will be integrated into current and upcoming trials. Current trials for localized disease require larger cohorts of patients and these international trials pose both opportunities and challenges.

### **1:15 Introduction**

Jeffrey A. Toretsky, Georgetown University, Lombardi Cancer Center, Washington, DC

### **1:20 Progress Report for the Past Twenty-Five Years**

Michael P. Link, Stanford University School of Medicine, Stanford, CA

### **1:40 Novel Agents**

Peter M. Anderson, MD Anderson Cancer Center, Children's Cancer Hospital, Houston, TX

### **2:05 Novel Models**

Chand Khanna, National Cancer Institute, Center for Cancer Research, Rockville, MD

### **2:30 Orthopedic Updates**

R. Lor Randall, University of Utah, Salt Lake City, UT

### **2:55 International Challenges**

Mark L. Bernstein, IWK Health Center, Dalhousie University, Halifax, Nova Scotia

3:30pm–5:30pm

## **4500A ASPHO Business Meeting, Awards and Special Presentations**

FRY, Ballroom

Chair: William G. Woods, Aflac Cancer Center and Blood Disorders Service, Atlanta, GA

### **3:30 President's Remarks and Annual Business Meeting**

### **4:00\* Young Investigator Award Recipient**

**Marcela I. Popescu**

**The Role of Helios in the Pathogenesis of B-Cell Malignancies.** Marcela I. Popescu, Zafer Gurel, Erik Ranheim, Ken H. Young, Kathleen M. Sakamoto, Sinisa Dovat. *Publication 4500A.1*

### **4:15\* Young Investigator Award Recipient**

**Loretta M.S. Lau**

**Differential Modulation of p73 Isoforms by COX Inhibitor in Neuroblastoma.** Loretta M.S. Lau, Jennifer K. Nugent, Meredith S. Irwin. *Publication 4500A.2*

### **4:30 Frank A. Oski Memorial Lecture**

**Translating Our Evolving Knowledge of Neuroblastoma Biology to Patients with the Disease**

**John M. Maris, Children's Hospital of Philadelphia, Philadelphia, PA**

Neuroblastoma is one of several pediatric cancers that continues to exact a disproportionate amount of childhood morbidity and mortality. We have made tremendous progress in identifying tumor specific biomarkers of tumor aggressiveness that are used to help clinicians stratify therapy. However, it is disappointing, perhaps even shocking, that overall survival rates for high-risk neuroblastoma have been stagnant over the last two decades despite a dramatic intensification in chemoradiotherapy. This lecture will develop the theme that any substantive progress in improving neuroblastoma cure rates will be derived from an improved understanding of the genetic basis of the disease. Recent advances in identifying molecular pathways that can be leveraged to develop new treatments for high-risk neuroblastoma will be discussed. This lecture will demonstrate that the practical issues related to making advances in a relatively rare disease can be overcome, and that the time is right to make rapid advances against a formidable and enigmatic childhood malignancy.

### **5:15 Distinguished Career Award Recipient**

George R. Buchanan, University of Texas Southwestern Medical Center, Dallas, TX

5:30pm–6:15pm

## **4600A ASPHO Distinguished Career Award Reception**

FRY, Imperial

6:00pm–9:00pm

**4700A LWPES President's Poster Session & Reception**

FRY, Canadian

6:30pm–7:30pm

**4800A Return of the Battle of the ASPHO Superstars**

FRY, Ballroom

Chairs: Guy Young, Children's Hospital Los Angeles, Los Angeles, CA; and Judith F. Margolin, Baylor College of Medicine, Houston, TX

Several years ago, Dr. Holcombe Grier organized and hosted an event in which two teams of seasoned pediatric hematology-oncology veterans matched wits in a quiz show format. Bragging rights went to those who answered the most questions correctly. The popular and fun event returns this year, with two teams answering a wide array of questions on various aspects of pediatric hematology/oncology ranging from the interesting and esoteric to the historic. Enjoy refreshments with your colleagues and match your wits with the ASPHO veterans on stage to see how many questions you know the answers to.